tag martin-fox 
Drug Discovery World
NOVEMBER 9, 2023
Martin Pflügler, PhD, CEO, TWYCE, on: ‘Two targets, two signals: a combinatorial concept for cancer therapy with bispecific antibodies directed to CD3 and CD28’. Kris Ver Donck, Vice President, Marketing & Applications, FOx BIOSYSTEMS, on: ‘Using FO-SPR to select for efficient antigen binders in phage display’.
Pharma Marketing Network
JUNE 8, 2020
I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.
Expert insights. Personalized for you.
52 
Let's personalize your content